Skip to Content

Find Comparable Stocks for AbbVie Inc.

AbbVie Inc.

ABBV - NYQ
Life Sciences
Pharmaceutical Preparations
Country
USA
Market Cap
$378.3B
Dividend Yield
3%
Beta
0.60 (Low)
Trading Volume
6.8M (Moderate)
Momentum
Very Weak Strong Very Strong
Value vs. Growth
Deep Value Fair Value Rapid Growth
Quality
Poor Good Excellent
Size
Micro Mega Cap Mega Cap

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Valuation
Financials
Momentum
Analyst Ratings
Trailing P/E
89.29
Forward P/E
17.48
PEG Ratio
0.45
Price/Book
113.77
EV/EBITDA
29.50
EV/Revenue
7.81

Income Statement

Revenue (TTM)
$56.3B
Gross Profit (TTM)
$39.6B
EBITDA
$26.2B

Financial Ratios

Profit Margin
8%
Operating Margin (TTM)
33%
Gross Profit Margin
70%
EBITDA Margin
47%
ROE (TTM)
62%
ROA (TTM)
8%

Growth

Quarterly Revenue Growth (YoY)
6%
Quarterly Earnings Growth (YoY)
-12%
52-Week Range
$149.56
$214.29
$215.66
50-Day Moving Average
$187.52
Price vs. 50-Day MA
14.28%
200-Day Moving Average
$183.26
Price vs. 200-Day MA
16.93%
Analyst Ratings Distribution
0
0
10
11
6
Strong Sell Strong Buy
Median Price Target
$209.13
Price to Target
102%

Johnson & Johnson

JNJ - NYQ
View JNJ's Comps
A
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Life Sciences
Pharmaceutical Preparations
Market Cap: $397.3B
Volume: 12.0M (High)
Beta: 0.51 (Low)
Dividend Yield: 3%
Neutral Momentum
Fair Value
Average Quality
Mega Cap

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Compare
Valuation
Financials
Momentum
Ratings

Johnson & Johnson is a diversified healthcare company that includes pharmaceuticals among its business segments, making it comparable to AbbVie in terms of industry and market presence. Both companies have a commitment to innovation and patient care.

correlation
B

correlation

Measures how closely the two stocks' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 29%

R-squared: 9%

This indicates a negligible relationship between the price movements of these stocks.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 7
  • ABBV in JNJ's comparables: No
  • JNJ in ABBV's comparables: Yes

A high score suggests the companies are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

financials
A

financials

Compares key financial metrics to assess operational similarity and financial health.

  • Revenue Growth: 6% vs 5%
  • Profit Margin: 8% vs 16%
  • ROE: 62% vs 20%
  • Operating Margin: 33% vs 18%
  • Revenue (TTM): $56.3B vs $88.8B

A high score indicates similar financial performance, efficiency, and growth trajectories, suggesting comparable business models and market positions.

size
A+

size

Evaluates similarity in market capitalization, which can indicate comparable market influence, investor interest, and resource availability.

Market Cap: $378.3B vs $397.3B

Size Category: Mega Cap vs Mega Cap

A high score suggests the companies are in the same size category, facing similar challenges and opportunities in terms of market presence and financial flexibility.

valuation
C

valuation

Compares valuation metrics to assess if the stocks are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 89.29 vs 28.50
  • P/B Ratio: 113.77 vs 5.56
  • EV/EBITDA: 29.50 vs 16.52
  • Forward P/E: 17.48 vs 15.58
  • PEG Ratio: 0.45 vs 1.12

A high score indicates that the market values these companies similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

sector
A+

sector

Compares the sector and industry classification of both companies, allowing for partial matches.

  • Sector: LIFE SCIENCES vs LIFE SCIENCES
  • Industry: PHARMACEUTICAL PREPARATIONS vs PHARMACEUTICAL PREPARATIONS

A high score indicates that the companies operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends. Partial matches are considered for more nuanced comparisons.

analyst ratings
A+

analyst ratings

Compares the consensus of analyst opinions on both stocks.

  • ABBV Rating: Buy
  • JNJ Rating: Buy

A high score suggests that analysts view both stocks similarly in terms of their future prospects and investment potential.

geo
A+

geo

Evaluates the geographical similarity of the companies based on country, currency, exchange, and address.

  • ABBV Country: USA
  • JNJ Country: USA
  • Currency: USD vs USD
  • Exchange: NYQ vs NYQ

A high score indicates that both companies operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

volatility
A+

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • ABBV Beta: 0.60 (Low)
  • JNJ Beta: 0.51 (Low)

A high score suggests both stocks have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

business similarity
A

business similarity

Assesses the similarity of the companies' business models, products, and services.

This score is based on an analysis of the companies' business descriptions, major products, and revenue streams.

A high score indicates that the companies have similar core businesses, target markets, and revenue generation strategies.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • ABBV Price vs 200-day MA: 116.93%
  • JNJ Price vs 200-day MA: 106.67%

A high score indicates both stocks are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • ABBV Dividend Yield: 3%
  • JNJ Dividend Yield: 3%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

Trailing P/E
28.50
Forward P/E
15.58
PEG Ratio
1.12
Price/Book
5.56
EV/EBITDA
16.52
EV/Revenue
4.61

Income Statement

Revenue (TTM)
$88.8B
Gross Profit (TTM)
$61.8B
EBITDA
$29.9B

Financial Ratios

Profit Margin
16%
Operating Margin (TTM)
18%
Gross Profit Margin
N/A
EBITDA Margin
N/A
ROE (TTM)
20%
ROA (TTM)
8%

Growth

Quarterly Revenue Growth (YoY)
5%
Quarterly Earnings Growth (YoY)
-3%
52-Week Range
$138.68
$165.02
$166.43
50-Day Moving Average
$150.65
Price vs. 50-Day MA
9.54%
200-Day Moving Average
$154.70
Price vs. 200-Day MA
6.67%
Analyst Ratings Distribution
0
0
11
7
4
Strong Sell Strong Buy
Median Price Target
$168.44
Price to Target
98%

Pfizer Inc.

PFE - NYQ
View PFE's Comps
A
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Life Sciences
Pharmaceutical Preparations
Market Cap: $146.6B
Volume: 24.6M (High)
Beta: 0.54 (Low)
Dividend Yield: 7%
Weak Momentum
Value
Average Quality
Large Cap

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Compare
Valuation
Financials
Momentum
Ratings

Pfizer Inc. is a global pharmaceutical giant known for its extensive research and development in various therapeutic areas, akin to AbbVie's operations. Both companies have a history of strong earnings and dividends.

correlation
B+

correlation

Measures how closely the two stocks' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 37%

R-squared: 14%

This indicates a weak positive relationship between the price movements of these stocks.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 7
  • ABBV in PFE's comparables: No
  • PFE in ABBV's comparables: Yes

A high score suggests the companies are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

financials
A-

financials

Compares key financial metrics to assess operational similarity and financial health.

  • Revenue Growth: 6% vs 22%
  • Profit Margin: 8% vs 13%
  • ROE: 62% vs 9%
  • Operating Margin: 33% vs 16%
  • Revenue (TTM): $56.3B vs $63.6B

A high score indicates similar financial performance, efficiency, and growth trajectories, suggesting comparable business models and market positions.

size
A+

size

Evaluates similarity in market capitalization, which can indicate comparable market influence, investor interest, and resource availability.

Market Cap: $378.3B vs $146.6B

Size Category: Mega Cap vs Large Cap

A high score suggests the companies are in the same size category, facing similar challenges and opportunities in terms of market presence and financial flexibility.

valuation
C

valuation

Compares valuation metrics to assess if the stocks are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 89.29 vs 18.35
  • P/B Ratio: 113.77 vs 1.69
  • EV/EBITDA: 29.50 vs 10.59
  • Forward P/E: 17.48 vs 8.87
  • PEG Ratio: 0.45 vs 0.18

A high score indicates that the market values these companies similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

sector
A+

sector

Compares the sector and industry classification of both companies, allowing for partial matches.

  • Sector: LIFE SCIENCES vs LIFE SCIENCES
  • Industry: PHARMACEUTICAL PREPARATIONS vs PHARMACEUTICAL PREPARATIONS

A high score indicates that the companies operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends. Partial matches are considered for more nuanced comparisons.

analyst ratings
A+

analyst ratings

Compares the consensus of analyst opinions on both stocks.

  • ABBV Rating: Buy
  • PFE Rating: Hold

A high score suggests that analysts view both stocks similarly in terms of their future prospects and investment potential.

geo
A+

geo

Evaluates the geographical similarity of the companies based on country, currency, exchange, and address.

  • ABBV Country: USA
  • PFE Country: USA
  • Currency: USD vs USD
  • Exchange: NYQ vs NYQ

A high score indicates that both companies operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

volatility
A+

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • ABBV Beta: 0.60 (Low)
  • PFE Beta: 0.54 (Low)

A high score suggests both stocks have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

business similarity
A

business similarity

Assesses the similarity of the companies' business models, products, and services.

This score is based on an analysis of the companies' business descriptions, major products, and revenue streams.

A high score indicates that the companies have similar core businesses, target markets, and revenue generation strategies.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • ABBV Price vs 200-day MA: 116.93%
  • PFE Price vs 200-day MA: 93.09%

A high score indicates both stocks are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

dividend
C+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • ABBV Dividend Yield: 3%
  • PFE Dividend Yield: 7%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

Trailing P/E
18.66
Forward P/E
8.87
PEG Ratio
0.18
Price/Book
1.69
EV/EBITDA
10.59
EV/Revenue
3.02

Income Statement

Revenue (TTM)
$63.6B
Gross Profit (TTM)
$47.2B
EBITDA
$23.3B

Financial Ratios

Profit Margin
13%
Operating Margin (TTM)
16%
Gross Profit Margin
N/A
EBITDA Margin
N/A
ROE (TTM)
9%
ROA (TTM)
5%

Growth

Quarterly Revenue Growth (YoY)
22%
Quarterly Earnings Growth (YoY)
-98%
52-Week Range
$23.71
$25.87
$30.55
50-Day Moving Average
$26.31
Price vs. 50-Day MA
-1.67%
200-Day Moving Average
$27.79
Price vs. 200-Day MA
-6.91%
Analyst Ratings Distribution
0
1
13
6
3
Strong Sell Strong Buy
Median Price Target
$31.09
Price to Target
83%

Amgen Inc.

AMGN - NMS
View AMGN's Comps
A
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Life Sciences
Biological Products, (no Disgnostic Substances)
Market Cap: $170.7B
Volume: 3.1M (Moderate)
Beta: 0.52 (Low)
Dividend Yield: 3%
Neutral Momentum
Fair Value
Good Quality
Large Cap

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.

Compare
Valuation
Financials
Momentum
Ratings

Amgen Inc. is a leading biotechnology company that develops therapies for serious illnesses, similar to AbbVie's focus on biopharmaceuticals in the life sciences sector. Both companies have substantial market capitalization and a strong pipeline of products.

correlation
B

correlation

Measures how closely the two stocks' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 29%

R-squared: 9%

This indicates a negligible relationship between the price movements of these stocks.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 3
  • ABBV in AMGN's comparables: Yes
  • AMGN in ABBV's comparables: Yes

A high score suggests the companies are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

financials
A

financials

Compares key financial metrics to assess operational similarity and financial health.

  • Revenue Growth: 6% vs 11%
  • Profit Margin: 8% vs 12%
  • ROE: 62% vs 68%
  • Operating Margin: 33% vs 52%
  • Revenue (TTM): $56.3B vs $33.4B

A high score indicates similar financial performance, efficiency, and growth trajectories, suggesting comparable business models and market positions.

size
A+

size

Evaluates similarity in market capitalization, which can indicate comparable market influence, investor interest, and resource availability.

Market Cap: $378.3B vs $170.7B

Size Category: Mega Cap vs Large Cap

A high score suggests the companies are in the same size category, facing similar challenges and opportunities in terms of market presence and financial flexibility.

valuation
C

valuation

Compares valuation metrics to assess if the stocks are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 89.29 vs 42.04
  • P/B Ratio: 113.77 vs 28.54
  • EV/EBITDA: 29.50 vs 16.16
  • Forward P/E: 17.48 vs 15.08
  • PEG Ratio: 0.45 vs 1.06

A high score indicates that the market values these companies similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

sector
A+

sector

Compares the sector and industry classification of both companies, allowing for partial matches.

  • Sector: LIFE SCIENCES vs LIFE SCIENCES
  • Industry: PHARMACEUTICAL PREPARATIONS vs BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

A high score indicates that the companies operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends. Partial matches are considered for more nuanced comparisons.

analyst ratings
A+

analyst ratings

Compares the consensus of analyst opinions on both stocks.

  • ABBV Rating: Buy
  • AMGN Rating: Hold

A high score suggests that analysts view both stocks similarly in terms of their future prospects and investment potential.

geo
A+

geo

Evaluates the geographical similarity of the companies based on country, currency, exchange, and address.

  • ABBV Country: USA
  • AMGN Country: USA
  • Currency: USD vs USD
  • Exchange: NYQ vs NMS

A high score indicates that both companies operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

volatility
A+

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • ABBV Beta: 0.60 (Low)
  • AMGN Beta: 0.52 (Low)

A high score suggests both stocks have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

business similarity
B+

business similarity

Assesses the similarity of the companies' business models, products, and services.

This score is based on an analysis of the companies' business descriptions, major products, and revenue streams.

A high score indicates that the companies have similar core businesses, target markets, and revenue generation strategies.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • ABBV Price vs 200-day MA: 116.93%
  • AMGN Price vs 200-day MA: 103.86%

A high score indicates both stocks are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • ABBV Dividend Yield: 3%
  • AMGN Dividend Yield: 3%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

Trailing P/E
41.93
Forward P/E
15.08
PEG Ratio
1.06
Price/Book
28.54
EV/EBITDA
16.16
EV/Revenue
6.46

Income Statement

Revenue (TTM)
$33.4B
Gross Profit (TTM)
$23.0B
EBITDA
$15.2B

Financial Ratios

Profit Margin
12%
Operating Margin (TTM)
52%
Gross Profit Margin
N/A
EBITDA Margin
N/A
ROE (TTM)
68%
ROA (TTM)
6%

Growth

Quarterly Revenue Growth (YoY)
11%
Quarterly Earnings Growth (YoY)
-19%
52-Week Range
$251.27
$317.82
$338.98
50-Day Moving Average
$283.10
Price vs. 50-Day MA
12.26%
200-Day Moving Average
$306.01
Price vs. 200-Day MA
3.86%
Analyst Ratings Distribution
1
2
14
9
5
Strong Sell Strong Buy
Median Price Target
$315.95
Price to Target
101%

Merck & Co., Inc.

MRK - NYQ
View MRK's Comps
A
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Life Sciences
Pharmaceutical Preparations
Market Cap: $236.1B
Volume: 6.2M (Moderate)
Beta: 0.36 (No Correlation)
Dividend Yield: 4%
Weak Momentum
Fair Value
Good Quality
Mega Cap

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Compare
Valuation
Financials
Momentum
Ratings

AbbVie Inc. is a biopharmaceutical company that specializes in immunology and oncology, positioning it as a comparable entity with similar market dynamics and challenges in the pharmaceutical landscape.

correlation
B

correlation

Measures how closely the two stocks' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 32%

R-squared: 10%

This indicates a weak positive relationship between the price movements of these stocks.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 6
  • ABBV in MRK's comparables: Yes
  • MRK in ABBV's comparables: No

A high score suggests the companies are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

financials
A

financials

Compares key financial metrics to assess operational similarity and financial health.

  • Revenue Growth: 6% vs 7%
  • Profit Margin: 8% vs 27%
  • ROE: 62% vs 41%
  • Operating Margin: 33% vs 34%
  • Revenue (TTM): $56.3B vs $64.2B

A high score indicates similar financial performance, efficiency, and growth trajectories, suggesting comparable business models and market positions.

size
A+

size

Evaluates similarity in market capitalization, which can indicate comparable market influence, investor interest, and resource availability.

Market Cap: $378.3B vs $236.1B

Size Category: Mega Cap vs Mega Cap

A high score suggests the companies are in the same size category, facing similar challenges and opportunities in terms of market presence and financial flexibility.

valuation
C

valuation

Compares valuation metrics to assess if the stocks are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 89.29 vs 13.87
  • P/B Ratio: 113.77 vs 5.05
  • EV/EBITDA: 29.50 vs 10.01
  • Forward P/E: 17.48 vs 10.28
  • PEG Ratio: 0.45 vs 0.85

A high score indicates that the market values these companies similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

sector
A+

sector

Compares the sector and industry classification of both companies, allowing for partial matches.

  • Sector: LIFE SCIENCES vs LIFE SCIENCES
  • Industry: PHARMACEUTICAL PREPARATIONS vs PHARMACEUTICAL PREPARATIONS

A high score indicates that the companies operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends. Partial matches are considered for more nuanced comparisons.

analyst ratings
A+

analyst ratings

Compares the consensus of analyst opinions on both stocks.

  • ABBV Rating: Buy
  • MRK Rating: Buy

A high score suggests that analysts view both stocks similarly in terms of their future prospects and investment potential.

geo
A+

geo

Evaluates the geographical similarity of the companies based on country, currency, exchange, and address.

  • ABBV Country: USA
  • MRK Country: USA
  • Currency: USD vs USD
  • Exchange: NYQ vs NYQ

A high score indicates that both companies operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

volatility
A-

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • ABBV Beta: 0.60 (Low)
  • MRK Beta: 0.36 (No Correlation)

A high score suggests both stocks have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

business similarity
A-

business similarity

Assesses the similarity of the companies' business models, products, and services.

This score is based on an analysis of the companies' business descriptions, major products, and revenue streams.

A high score indicates that the companies have similar core businesses, target markets, and revenue generation strategies.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • ABBV Price vs 200-day MA: 116.93%
  • MRK Price vs 200-day MA: 84.90%

A high score indicates both stocks are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • ABBV Dividend Yield: 3%
  • MRK Dividend Yield: 4%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

Trailing P/E
13.83
Forward P/E
10.28
PEG Ratio
0.85
Price/Book
5.05
EV/EBITDA
10.01
EV/Revenue
4.01

Income Statement

Revenue (TTM)
$64.2B
Gross Profit (TTM)
$49.5B
EBITDA
$29.1B

Financial Ratios

Profit Margin
27%
Operating Margin (TTM)
34%
Gross Profit Margin
N/A
EBITDA Margin
N/A
ROE (TTM)
41%
ROA (TTM)
14%

Growth

Quarterly Revenue Growth (YoY)
7%
Quarterly Earnings Growth (YoY)
-33%
52-Week Range
$81.04
$93.48
$132.67
50-Day Moving Average
$94.57
Price vs. 50-Day MA
-1.15%
200-Day Moving Average
$110.10
Price vs. 200-Day MA
-15.10%
Analyst Ratings Distribution
0
0
9
12
5
Strong Sell Strong Buy
Median Price Target
$112.78
Price to Target
83%

Gilead Sciences, Inc.

GILD - NMS
View GILD's Comps
A
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Life Sciences
Biological Products, (no Disgnostic Substances)
Market Cap: $143.8B
Volume: 4.1M (Moderate)
Beta: 0.24 (No Correlation)
Dividend Yield: 3%
Very Strong Momentum
Fair Value
Good Quality
Large Cap

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Compare
Valuation
Financials
Momentum
Ratings

Gilead Sciences, Inc. specializes in antiviral drugs and has a robust portfolio, comparable to AbbVie’s offerings in the pharmaceutical preparations industry. Both companies are known for their innovative research and development.

correlation
B-

correlation

Measures how closely the two stocks' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 23%

R-squared: 5%

This indicates a negligible relationship between the price movements of these stocks.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 5
  • ABBV in GILD's comparables: Yes
  • GILD in ABBV's comparables: Yes

A high score suggests the companies are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

financials
A-

financials

Compares key financial metrics to assess operational similarity and financial health.

  • Revenue Growth: 6% vs 6%
  • Profit Margin: 8% vs 2%
  • ROE: 62% vs 2%
  • Operating Margin: 33% vs 33%
  • Revenue (TTM): $56.3B vs $28.8B

A high score indicates similar financial performance, efficiency, and growth trajectories, suggesting comparable business models and market positions.

size
A+

size

Evaluates similarity in market capitalization, which can indicate comparable market influence, investor interest, and resource availability.

Market Cap: $378.3B vs $143.8B

Size Category: Mega Cap vs Large Cap

A high score suggests the companies are in the same size category, facing similar challenges and opportunities in terms of market presence and financial flexibility.

valuation
B

valuation

Compares valuation metrics to assess if the stocks are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 89.29 vs 303.89
  • P/B Ratio: 113.77 vs 7.39
  • EV/EBITDA: 29.50 vs 35.64
  • Forward P/E: 17.48 vs 14.51
  • PEG Ratio: 0.45 vs 0.61

A high score indicates that the market values these companies similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

sector
A+

sector

Compares the sector and industry classification of both companies, allowing for partial matches.

  • Sector: LIFE SCIENCES vs LIFE SCIENCES
  • Industry: PHARMACEUTICAL PREPARATIONS vs BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

A high score indicates that the companies operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends. Partial matches are considered for more nuanced comparisons.

analyst ratings
A+

analyst ratings

Compares the consensus of analyst opinions on both stocks.

  • ABBV Rating: Buy
  • GILD Rating: Buy

A high score suggests that analysts view both stocks similarly in terms of their future prospects and investment potential.

geo
A+

geo

Evaluates the geographical similarity of the companies based on country, currency, exchange, and address.

  • ABBV Country: USA
  • GILD Country: USA
  • Currency: USD vs USD
  • Exchange: NYQ vs NMS

A high score indicates that both companies operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

volatility
B

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • ABBV Beta: 0.60 (Low)
  • GILD Beta: 0.24 (No Correlation)

A high score suggests both stocks have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

business similarity
B+

business similarity

Assesses the similarity of the companies' business models, products, and services.

This score is based on an analysis of the companies' business descriptions, major products, and revenue streams.

A high score indicates that the companies have similar core businesses, target markets, and revenue generation strategies.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • ABBV Price vs 200-day MA: 116.93%
  • GILD Price vs 200-day MA: 137.36%

A high score indicates both stocks are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • ABBV Dividend Yield: 3%
  • GILD Dividend Yield: 3%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

Trailing P/E
303.79
Forward P/E
14.51
PEG Ratio
0.61
Price/Book
7.39
EV/EBITDA
35.64
EV/Revenue
5.50

Income Statement

Revenue (TTM)
$28.8B
Gross Profit (TTM)
$22.5B
EBITDA
$13.5B

Financial Ratios

Profit Margin
2%
Operating Margin (TTM)
33%
Gross Profit Margin
N/A
EBITDA Margin
N/A
ROE (TTM)
2%
ROA (TTM)
11%

Growth

Quarterly Revenue Growth (YoY)
6%
Quarterly Earnings Growth (YoY)
25%
52-Week Range
$60.24
$115.48
$117.39
50-Day Moving Average
$98.59
Price vs. 50-Day MA
17.13%
200-Day Moving Average
$84.07
Price vs. 200-Day MA
37.36%
Analyst Ratings Distribution
0
0
11
15
5
Strong Sell Strong Buy
Median Price Target
$109.62
Price to Target
105%
Toggle between similar stocks and ETFs for comparison.

Loading comparable stocks ...

Johnson & Johnson

JNJ - NYQ
A
$165.02 +1.29 (0.79%)
Life Sciences
Pharmaceutical Preparations
Market Cap: $397.3B
Volume: 12.0M (High)
Beta: 0.51 (Low)
Dividend Yield: 3%
Neutral Momentum
Fair Value
Average Quality
Mega Cap
$165.02
$138.68 $166.43

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow...

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Pfizer Inc.

PFE - NYQ
A
$25.87 +0.12 (0.47%)
Life Sciences
Pharmaceutical Preparations
Market Cap: $146.6B
Volume: 24.6M (High)
Beta: 0.54 (Low)
Dividend Yield: 7%
Weak Momentum
Value
Average Quality
Large Cap
$25.87
$23.71 $30.55

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Cha...

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Amgen Inc.

AMGN - NMS
A
$317.82 +1.25 (0.39%)
Life Sciences
Biological Products, (no Disgnostic Substances)
Market Cap: $170.7B
Volume: 3.1M (Moderate)
Beta: 0.52 (Low)
Dividend Yield: 3%
Neutral Momentum
Fair Value
Good Quality
Large Cap
$317.82
$251.27 $338.98

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry,...

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.

Merck & Co., Inc.

MRK - NYQ
A
$93.48 +0.29 (0.31%)
Life Sciences
Pharmaceutical Preparations
Market Cap: $236.1B
Volume: 6.2M (Moderate)
Beta: 0.36 (No Correlation)
Dividend Yield: 4%
Weak Momentum
Fair Value
Good Quality
Mega Cap
$93.48
$81.04 $132.67

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Gilead Sciences, Inc.

GILD - NMS
A
$115.48 +0.04 (0.03%)
Life Sciences
Biological Products, (no Disgnostic Substances)
Market Cap: $143.8B
Volume: 4.1M (Moderate)
Beta: 0.24 (No Correlation)
Dividend Yield: 3%
Very Strong Momentum
Fair Value
Good Quality
Large Cap
$115.48
$60.24 $117.39

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepati...

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.